Neurotoxins and medicinals for the treatment of Parkinson’s disease. Part 2: dopamine receptors and their agonists

Author： Kadieva M.   Oganesyan É.   Mutsueva S.  

Publisher： Springer Publishing Company

ISSN： 0091-150X

Source： Pharmaceutical Chemistry Journal, Vol.39, Iss.10, 2005-10, pp. : 520-532

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Neurotoxins and medicinals for the treatment of Parkinson’s disease. Part 3: Drugs indirectly influencing the dopaminergic system (a review)

By Kadieva M.   Oganesyan É.   Mutsueva S.  

Pharmaceutical Chemistry Journal, Vol. 39, Iss. 11, 2005-11 ,pp. : 565-573

Springer Publishing Company

Access to resources Recommend Favorite

Dopamine agonists in Parkinson’s disease

By Tintner Ron   Jankovic Joseph  

Expert Opinion on Investigational Drugs, Vol. 12, Iss. 11, 2003-11 ,pp. : 1803-1820

Informa Healthcare

Access to resources Recommend Favorite

Dopamine D3 Agonists in the Treatment of Parkinson&aposs Disease

By  

Current Topics in Medicinal Chemistry, Vol. 15, Iss. 10, 2015-05 ,pp. : 908-926

Bentham Science Publishers

Access to resources Recommend Favorite

Neurotoxins and Drugs for the Treatment of Parkinson's Disease. Part I: Neurotoxins, Levodopa, and Agents Influencing Dopamine Metabolism (A Review)

By Kadieva M.   Oganesyan E.   Mutsueva S.  

Pharmaceutical Chemistry Journal, Vol. 39, Iss. 9, 2005-09 ,pp. : 453-465

Springer Publishing Company

Access to resources Recommend Favorite

Dopamine Agonists in Parkinson’s Disease: What is Their Role in Early Treatment?

By Stocchi F.  

CNS Drugs, Vol. 10, Iss. 3, 1998-09 ,pp. : 159-170

Adis International

Access to resources Recommend Favorite